LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! Here we are again, spring is almost here…

It has been a quiet week, without too many updates, but the ones we have are quite significant—things that can truly help us in the battle.

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• ACCEL Trial Phase 1
  ​A phase I clinical study is evaluating Actinium-225-PSMA-62 (Ac-225-PSMA-62), a novel radioligand therapy. It focuses on patients who have progressed after androgen deprivation therapy (ADT) and at least one chemotherapy agent. Ac-225-PSMA-62 combines Actinium-225, an alpha-emitting radioisotope, with PSMA-62, a targeting ligand which is supposed to be more targeted than current Lutetium-177 ligands, reducing side effects. The trial is open to oligometastatic hormone-sensitive prostate cancer (OmHSPC)�patients and those with metastatic castration-resistant prostate cancer (mCRPC).
  ​
• TLX591 Phase 3 Trial in Miami​
  Telix Pharmaceuticals has initiated its ProstACT Global Phase 3 clinical trial for TLX591 (aka J591) at the Biogenix Molecular Research Center in Miami, Florida4. TLX591 is a radiopharmaceutical that targets prostate-specific membrane antigen (PSMA) and combines Lutetium-177 with a PSMA-targeting antibody4. The trial is actively recruiting eligible patients in the Miami area5. TLX591 employs a monoclonal antibody, rosopatamab, to carry Lutetium-177 to PSMA, binding with higher affinity and specificity, potentially targeting smaller, less detectable metastases.
  ​
• OncoACP3 Phase 1 Trial
  68Ga-OncoACP3�is a small-molecule radiotracer for non-invasive detection and staging of metastatic prostate cancer6. It exhibits high affinity for Acid Phosphatase 3 (ACP3), an enzyme abundantly expressed in prostate cancer tissues but largely absent in normal organs. Preclinical evaluations have demonstrated rapid and selective accumulation in tumour masses with extremely low uptake in normal organs. This would make ACP3 a better target than PSMA. At the moment, it is being evaluated as a radiotracer, but it is also being explored as a theranostic agent when conjugated with Lutetium-177 (¹⁷⁷Lu) and Actinium-225 (²²⁵Ac).

Preclinical Research

• Google’s AI Co-Scientist​
  Google has introduced an AI-powered “co-scientist” to assist biomedical researchers. This AI can generate hypotheses, analyze complex datasets, and identify novel scientific insights by mimicking the scientific method. Early testing has shown the AI can independently hypothesize new gene transfer mechanisms and suggest potential treatments for liver fibrosis. The AI scans vast amounts of scientific literature, experimental data, and existing knowledge to identify gaps and propose novel ideas, handling massive datasets at speeds impossible for humans.
  ​
• New Smart mRNA Technology
  ​CancerVax, Inc. has validated its Smart mRNA technology for a universal cancer treatment platform. The nanoparticle is engineered to identify and attach to cells exhibiting surface proteins that are predominantly expressed on cancer cells. Upon binding, the nanoparticle releases a proprietary Smart mRNA payload designed to activate only in the presence of specific cancer genetic signatures, prompting the cancer cell to produce proteins resembling those of common diseases, such as measles.
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If you this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max